ABEO
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Abeona Therapeutics Inc. (ABEO) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A); its weakest is Momentum (D+). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.0) | A (4.3) | C- (2.1) | D+ (1.8) | C+ (2.6) | C+ (2.8) |
| 2026-11-10 | B- (3.0) | A+ (4.6) | C- (2.1) | C- (1.9) | C+ (2.6) | C+ (2.8) |
| 2026-11-03 | B- (3.0) | A+ (4.6) | C- (2.1) | C- (2.0) | C+ (2.7) | C+ (2.8) |
| 2026-10-27 | B- (3.0) | A+ (4.5) | C- (2.1) | C (2.2) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | B- (3.0) | A+ (4.5) | C- (2.1) | C- (2.1) | C+ (2.6) | B- (2.9) |